Table 2 Baseline characteristics of COMMD3 IHC cohort
From: COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
Mean follow-up (dead) | Â | 6.18Â yr | Feature | Â | n |
|---|---|---|---|---|---|
Mean follow-up (alive) |  | 17.4 yr | Receptor subtypes | ER + /HER2 +  | 27 |
Mean age at dx |  | 58.4 yr |  | ER + /HER2– | 320 |
Feature |  | n |  | ER–/HER2 +  | 29 |
Grade | 1 | 61 |  | ER–/HER2– | 77 |
2 | 232 | COMMD3 IHC score | 0 | 200 | |
3 | 164 | Â | -1 | 111 | |
Stage | I | 28 | Â | -2 | 81 |
II | 104 | Â | -3 | 27 | |
III | 14 | Â | -4 | 44 |